Proceedings of the ISPD '98 -The VIIIth Congress of the ISPD August 23 -26, 1998, Seoul, Korea Peritoneal Dialysis International, Vol. 19 (1999). Supp...
Author: Philippa Ball
9 downloads 2 Views 389KB Size
Proceedings of the ISPD '98 -The VIIIth Congress of the ISPD August 23 -26, 1998, Seoul, Korea Peritoneal Dialysis International, Vol. 19 (1999). Supplement 2

0896-8608/99 $3.00 + 00 Copyright © 1999 International Society for Peritoneal Dialysis Printed in Canada. AIl rights reserved.


Sarah Prichard Nephrology Division, Department of Medicine, McGi11 University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada

disease remains the most common cause C ardiovascular of mortality for patients with end-stage

DYSLIPIDEMIAS Hyperlipidemia, most importantly, hypercholesterolemia, is associated with the development of ASHD. This is clearly apparent for patients with familial hypercholesterolemia who have a defect in the lowdensity lipoprotein (LDL) receptor. These patients have premature CAD, usually presenting between their third and fifth decades; homozygote patients have clinically significant diseases as early as their KEY WORDS: Atherosclerosis risk; dyslipidemia. Correspondence to: S. Prichard, Nephrology Division, Department of Medicine, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec H3A lAl Canada.

Downloaded from by guest on February 26, 2014

renal disease (ESRD), accounting for up to 50% of deaths in this patient population. Furthermore, ESRD patients have a rate of coronary artery disease ( CAD ) far in excess of the non uremic population (1-5). Numerous studies have investigated the factors that contribute to this high incidence of cardiac disease amongst dialysis patients, and this paper focuses on a wide variety of such factors, particularly as they relate to peritoneal dialysis (PD) patients (Table 1). Emphasis in this paper is on the etiologies of atherosclerosis (ASHD), it being the most important cause of morbidity and mortality. However, left ventricular hypertrophy (LVH) has a high prevalence amongst ESRD patients and should be noted as an important and independent risk factor for death (6,7). Hypertension and anemia are treatable major determinants ofLVH. Additional contributing factors have been variably reported to include hyperparathyroidism and fluid overload. Congestive heart failure is also frequent and usually a symptom of advanced ASHD, or persistent cardiac overload, or both.

teens. However, hypercholesterolemia is a rare disease and of little relevance to the vast majority of sufferers of CAD. In large population studies, an association exists between elevated cholesterol levels and the incidence of CAD. In the last decade, evidence has emerged that treatment of elevated LDL cholesterol dramatically improves the outcome of patients with respect to ASHD in both primary and secondary prevention trials (8-10). This body of evidence is perhaps the most compelling to link lipids, specifically LDL cholesterol, to CAD. ESRD is associated with a high incidence of lipid abnormalities (11). Continuous ambulatory peritoneal dialysis (CAPD) patients have elevated levels of total cholesterol, LDL cholesterol, and apolipoprotein B (Apo B), and decreased levels ofhigh-density lipoprotein (HDL) cholesterol and apolipoprotein Al (Apo Al) (11). Because the elevation of Apo B is often greater than the elevation ofLDL cholesterol, CAPD patients

Lp(a). They have decreased HDL cholesterol and Apo Allevels. This constellation of abnormalities represents a highly atherogenic profile. HYPERHOMOCYSTEINEMIA Hyperhomocysteinemia is an independent risk factor for vascular disease in the non uremic population (26,27). Homocysteine is a highly reactive amino acid. It is toxic to vascular endothelium, it potentiates the auto-oxidation of LDL cholesterol, and it promotes thrombosis. In patients with established CAD, elevated total plasma homocysteine is a strong predictor of mortality. For renal failure patients, homocysteine has been demonstrated to be an independent risk factor for vascular disease (28-30). In one report, the ESRD patients in the upper two quintiles ofhomo cysteine compared with those in the lower three quintiles gave an odds ratio of2.9 for vascular events. Another report attributed an increased relative risk of 1% per 1 µmol/L increase in homocysteine concentration in ESRD patients (31). The incidence of abnormally elevated homocysteine levels is high in ESRD patients. The cause is multifactorial, but deficiencies of folate, vitamin B6, and vitamin B12, as well as reduced clearance ofhomocysteine by the kidney are all contributing factors (32,33). Thus, treatment includes adequate vitamin replacement and transplantation (34,35). Of note is the fact that supernormallevels of folate, B6, and B12 are often required; and even then, some patients retain elevated levels of homocysteine. Furthermore, abnormalities of endothelial function can persist even after correction of homocysteine level (36). A study in PD patients treated with fish oil demonstrated persistent elevation of homocysteine despite the treatments (37). HYPERINSULINEMIA



OBESITY Hyperinsulinemia has been identified as an independent risk factor for ischemic heart disease (38). Often, hyperinsulinemia is a signal of insulin resis tance and is associated with abdominal obesity. The latter has emerged as a risk factor, and attention has thus focused on the ratio ofhip measurement to waist measurement as a predictor of ASHD risk (39). Renal failure has long been known to be associated with insulin resistance and elevated insulin levels (40). Peritoneal dialysis patients are further disadvantaged in this regard because of constant glucose loading. Fernström et al have reported an increase of intra-abdominal fat in patients treated with CAPD (41), and they suggest that this increase may confer additional cardiovascular risk in these patients.

Downloaded from by guest on February 26, 2014

appear to have small, dense LDL, a particularly atherogenic form of LDL (12). In contrast, hemodialysis (HD) patients have decreased levels of HDL and Apo Al, and their levels of Apo B, total, and LDL cholesterol are relatively normal (13). As such, the lipid profile of a CAPD patient is more atherogenic than that of a HD counterpart. The lipid abnormalities associated with peritoneal dialysis have multifactorial causes. In uremia, there are abnormalities of lipoprotein lipase and hepatic lipase. In peritoneal dialysis, the loss of protein across the peritoneal membrane mimics to some extent nephrotic syndrome, which is characterized by hepatic overproduction of Apo B lipoproteins (VLDL and LDL). Elevated insulin levels also enhance the production ofLDL particles, and the constant glucose loading in PD patients produces a hyperinsulinemic state. In cell culture studies, diminished amino acids increased hepatocyte Apo B production (14), but addition of amino acids to peritoneal fluid has not consistently corrected the lipid abnormalities (15). Triglycerides are elevated in PD and HD patients, although significantly more so in PD patients (13). An increased level of triglycerides has a less clear causal relationship to ASHD. It is rarely found as an isolated risk factor, but is rather found in association with decreased HDL and elevated Apo B protein levels. In a recent eightyear follow-up in the Copenhagen Male Study, triglycerides were a strong risk factor for ASHD independent of other risk factors, including HDL cholesterol (16). As such, the frequently and significantly elevated triglyceride levels of CAPD patients may contribute to their risk profile. Lipoprotein(a) [Lp(a)] is a cholesterol-rich lipoprotein that has an LDL particle linked by disulfide bridges to apolipoprotein(a) [Apo(a)], which is a glycoprotein with high homology to plasminogen. In 1990, Lp(a) was reported in a case control study to be associated with an increased risk of coronary heart disease (17). This effect has been further demonstrated in a number of subsequent studies. In dialy sis patients, Lp(a) levels have consistently been reported as elevated, often more in CAPD than in HD patients (18-22). In the CAPD population, elevated Lp(a) levels have been further associated with malnutrition as judged by subjective global assessment and other nutritional markers such as albumin (23). Markers ofinflamma tion are also associated with Lp(a) elevation (24,25). Chronic inflammation as a risk factor for ASHD is discussed elsewhere in this paper. In summary, with respect to lipid abnormalities, PD patients have elevated total cholesterol, LDL cholesterol, apolipoprotein B, protein, triglycerides, and



SUMMARY Uremia in general and peritoneal dialysis in particular bring with them risk factors for the development of cardiovascular disease. These factors include multiple lipid abnormalities, hyperhomocysteinemia, abdominal obesity, chronic inflammation, hypoalbuminemia, oxidative stress, and AGE formation. When these are combined with conventional risk factors, one can appreciate why the incidence of cardiovascular disease is so high in peritoneal dialysis patients. Treatment strategies should address each of these risks appropriately.

STRESS REFERENCES In the general population, a decreased relative risk for fatal myocardial infarction has been reported in patients with the largest vitamin E and betacarotene consumption (47-49). In clinical trials, patients receiving antioxidants or antioxidants plus lipid-lowering therapy showed improvement in endothelial function. Conversely, high oxidant stress and oxidized LDL is implicated in the development of atherosclerosis. In uremia, increased oxidant stress exists, perhaps secondary to the impact of uremia alone, or to dietary deficiencies, or both (50). Oxidized LDL levels are measurable in uremia and are presumably taken up by the scavenger receptor that causes endothelial injury . MALNUTRITION, ADVANCED GLYCOSYLATION END-PRODUCTS, CALCIUM, PHOSPHATE Malnutrition, as indicated by hypoalbuminemia, is common in PD patients. As noted elsewhere in this paper, hypoalbuminemia is associated with elevated levels ofLp(a), CRP, and fibrinogen, all ofwhich may predispose to vascular disease. Foley et al report hypoalbuminemia as an independent factor for the development of de novo ischemic heart disease in renal failure (51). Advanced glycosylation end-products (AGEs) form between aldose sugars and lipids or proteins. AGEs exacerbate oxidative stress and accumulate in the

1. Raine AEG, for The European Dialysis Transplant Association Registry Committee. Combined report on regular dialysis and transplantation in Europe, XXII, 1991. Nephrol Dial Transplant. 1992; 2:7-35. 2. United States Department of Health and Human Services, Public Health Servic, National Institutes of Health. Survival probabilities and causes of death. In: USRDS Annual Data Report, 1991. Bethesda, MD: U.S. Renal Data System; 1991:31-40. 3. Churchill DN, Taylor W, Cook RJ, Laplante P, Barré P, Cartier P, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992; 19:214-34. 4. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995; 6:177-83. 5. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995; 6:184-91. 6. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Barré P. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990; 55:114-20. 7. Silberberg JS, Barré P, Prichard S, Sniderman AD. Left ventricular hypertrophy: An independent determinant of survival in end stage renal disease. Kidney Int. 1989; 36:286-90.

Downloaded from by guest on February 26, 2014

Peritoneal dialysis has been implicated as a state of chronic inflammation, particularly in patients using conventional, non physiologic dialysate solutions ( 42). This state of chronic inflammation may contribute to the low serum albumin seen in many patients. Elevated C-reactive protein (CRP) is reported with hypoalbuminemia. With respect to cardiovascular disease, CRP has been shown to add to the predictive value of total cholesterol and HDL cholesterol in determining risk of first myocardial infarction (43,44). Helnrich et al demonstrated a significant increase in CRP with increasing severity of ASHD. Elevated CRP was associated with an increased relative risk of mortality in hemodialysis patients (45). In a study of CAPD patients, elevated fibrinogen and fibrinolytic activ ity was associated with ASHD and low serum albumin levels ( 46). Inasmuch as these are acute phase reactants, their presence may implicate the inflammatory aspect of PD as a predisposing factor for vascular disease.

vessel wall. Peritoneal dialysis promotes the production of AGEs in the peritoneal vascular space and may do so systemically through glucose loading and insulin stimulation. Heavy calcification of the peripheral and coronary vessels has been observed for years in uremic populations. Recently, Block et al have implicated elevated phosphate as a risk factor for mortality (52). A further, poorly defined, high-risk group appears to be high transporters and, possibly, their chronic fluid overloaded state (53,54). Finally, conventional risk factors for cardiovascular disease -including hypertension, smoking, and passive lifestyle -are all relevant to PD patients.

1997; 17:236-42. 21. Guindeo C, Vega N, Fernandez AM, Palop L, Aguilar JA, Moreda A, et al. Lipoprotein(a) levels in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 1996; 16(Suppll):S236-40. 22. Kawaguchi Y, Kubo H, Yamamoto H, N akayama M, Yokoyama K, Shigematsu T, et al. Is atherosclerosis accelerated by CAPD? Perit Dial Int. 1996; 16(Suppl 1):S223-30. 23. Kang DH, Yoon KI, Lee SW, Kang SW, Choi KH, Lee HY, et al. Impact of nutritional status on serum lipoprotein(a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 1996; 16(Suppll):S241-5. 24. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 1997; 8:1889-98. 25. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 1998; 53:1336-42. 26. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med. 1991; 324:1149-55. 27. Nygard O, Nordrehaug JE, Ref sum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337:230-6. 28. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995; 6:121-5. 29. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. 1996; 50:S1117. 30. BostomAG, Lathrop L. Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52:10-20. 31. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998; 97:138-41. 32. Robinson K, Arheart K, Ref sum H, Brattstrom L, Boers G, Ueland P, et al, for the European COMAC group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 1998; 97:437-43. 33. BostomAG, Lathrop L. Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52:10-20. 34. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996; 46:147-52. 35. Mydlik M, Derziova K, Zemberova E. Metabolism of

Downloaded from by guest on February 26, 2014

8. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of Statin trials. Circulation. 1998; 97:946-52. 9. West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97:1440-5. 10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole T, et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335: 1001-9. 11. Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int. 1996; 16:S19-22. 12. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipop rotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997; 95:69-75. 13. Sniderman AD, Cianflone K, Kwiterovich PO Jr, Hutchinson T, Barre P, Prichard S. Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis. 1987; 65:257-64. 14. Prichard S, Cianflone K, SnidermanA. The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 1996; 16(Suppl1):S207-10. 15. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown ED. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997; 17:279-86. 16. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation. 1998; 97:1029-36. 17. Rosengren A, Wihelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. BMJ. 1990; 301: 1248-51. 18. Kronenberg F, König P, N eyer U, Auinger M, Prisbasnig A, Lang U, Reitinger J, Pinter G, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995; 6:110-20. 19. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, et al. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int. 1993;44:1062-70. 20. Kim SB, Yang WS, Kang ES, Min WK, Park JS. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Perit Dial Int.

62):S53-5. 45. Helnrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995; 73:374-9. 46. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int. 1997; 17:157-61. 47. Hoeschen RJ. Oxidative stress and cardiovascular dis ease. Can J Cardiol. 1997; 13:1021-5. 48. Gey KF, Burbacher GB, Stahelin S. Plasma levels of antioxidant vitamins in relation to ischemic heart dis ease and cancer. Clin Nutr.1987; 45:1368-77. 49. Rimm EM, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Dietary intake and risk of coronary heart disease among men. N Engl J Med. 1993; 328:1450-6. 50. Becker BN, Hemmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Sac Nephrol. 1997; 8:475-86. 51. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol. 1996; 7:728-36. 52. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31:607-17. 53. Blake PG. What is the problem with high transport ers? Perit Dial Int. 1997; 17:317-20. 54. Fried L. Higher membrane permeability predicts poorer patient survival. Perit Dial Int. 1997; 17: 387-401.

Downloaded from by guest on February 26, 2014

vitamin B6 and its requirement in chronic renal failure. Kidney Int. 1997; 52(Suppl 6):S56-9. 36. van Guldener C, Janssen MJFM, Lambert J, ter Wee PM, Donker AJM, Stehouwer CDA. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after longterm therapy. Perit Dial Int. 1998; 18:282-9. 37. Holdt B, Korten G, Knippel M, Lehmann JK, Claus R, Holtz M, et al. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int. 1996; 16(Suppll):S246-9. 38. Després JP, Lamarch B, Mauriege P, Cantin B, Dagenais G, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996; 334:952-7. 39. Gaudet D, Vohl MC, Perron P, Tremblay G, Gagné C, Lesiège D, et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation. 1998; 97:871-7. 40. Fliser P, Pacini G, Engelleiter R, Kautzky -Willer A, Prager R, Franek R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998; 33:1343-7. 41. Fernström A, Hylander B, Moritz A, Jacobsson H, Rössner S. Increase ofintra-abdominal fat in patients treated with CAPD. Perit Dial Int. 1998; 18:166-71. 42. Breborowicz A, Oreopoulos DG. Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications. Perit Dial Int. 1997; 17(Suppl2):S37-41. 43. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97:2007-11. 44. Wanner C, Zimmerman J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int. 1997; 52(Suppl

Suggest Documents